Dr. Saman Honarnejad, project manager for COILED (Center for Open Innovation in LEad Discovery) program at Pivot Park Screening Centre (PPSC) will be chairman and one of the speakers of the “Drug Discovery Strategies and Innovation” session at the “19th Annual Drug Discovery Summit in Berlin” (Stream 1, day 1). This conference brings together delegates representing leading biotech companies, global pharmaceutical organizations and internationally renowned academic institutions, covering key topics in drug discovery and medicinal chemistry fields.
PPSC, Radboudumc, Radboud University, Pansynth, BioAxis and Inntrest are partners in COILED, an EFRO subsidized collaborative drug discovery program focused on epigenetic targets. This program focuses on the discovery and optimization of lead candidates to modulate trained innate immunity, with the aim to treat hyper-inflammatory and immune deficiency-driven diseases like sepsis and cancer,” tells Honarnejad. In his presentation, Honarnejad will talk about the joint drug discovery efforts at PPSC and will focus on assay development and screening activities within COILED consortium, with an emphasis on “trained immunity”.
To learn more about the early drug discovery activities of PPSC , the Pivot Park Screening Centre’s booth can be visited at the exhibition section of DDS. In case you would like to schedule an appointment in advance, please contact us: email@example.com